Sumary of In omega-3 fatty acid trials, EPA alone yields greater CV risk reduction vs. EPA plus DHA:
- July 22, 2021 1 min read Source/Disclosures Published by: Disclosures: Khan reports no relevant financial disclosures.
- Back to Healio In a meta-analysis of omega-3 fatty acid trials, eicosapentaenoic acid monotherapy yielded the greatest reduction in CV risk vs.
- Bhatt “In this systematic review and meta-analysis, we noted moderate certainty of evidence favoring omega-3 fatty acids for reducing CV mortality and outcomes,” Cardiology Today Intervention Section Editor Deepak L.
- ” Source: Adobe Stock Bhatt and colleagues analyzed the effectiveness of omega-3 fatty acids on CV outcomes while examining the variability in EPA compared with a combination of EPA and DHA.
- The researchers evaluated CV mortality, nonfatal CV outcomes, bleeding and atrial fibrillation in a meta-analysis of 38 randomized clinical trials of omega-3 fatty acids, categorized by EPA monotherapy or EPA/DHA therapy.
- The clinical trials analyzed were published before June 7, 2021. In 149,051 individuals who participated in the 38 trials, omega-3 fatty acid use correlated with reduced risk for CV mortality (RR = 0.93;
- “This meta-analysis provides reassurance about the role of omega-3 fatty acids, specifically prescription EPA,” Bhatt said in a press release.